Apararenone (INN) (developmental code name MT-3995) is a nonsteroidal antimineralocorticoid which is under development by Mitsubishi Tanabe Pharma for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.

[1][2][3] It was also previously being developed for the treatment of hypertension, but development was discontinued for this indication.

[1] Apararenone acts as a highly selective antagonist of the mineralocorticoid receptor (Ki < 50 nM), the receptor for aldosterone.

[1][2][3] As of 2017, it is in phase II clinical trials.

This drug article relating to the cardiovascular system is a stub.